New imaging biomarkers for predicting Alzheimer's disease progression
Identifying Imaging Biomarkers Predictive of Disability Progression in Alzheimer's Disease: Pilot Study
This study is testing if advanced brain scans can help us see how Alzheimer's disease gets worse over time in people who are just starting to show symptoms.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 60 Years to 90 Years |
| Sex | All |
| Sponsor | Poitiers University Hospital Academic / other |
| Locations | 1 site (Poitiers) |
| Trial ID | NCT05939362 on ClinicalTrials.gov |
What this trial studies
This study investigates the use of ultra-high field 7T MRI and Magnetic Resonance Spectroscopy (MRS) to identify metabolic changes associated with the progression of Alzheimer's disease. By employing advanced imaging techniques, the study aims to provide insights into the metabolic dysregulations that contribute to neuronal death in early-stage Alzheimer's patients. Participants will undergo MRI follow-ups to monitor these changes over time, enhancing our understanding of the disease's progression.
Who should consider this trial
Good fit: Ideal candidates are French-speaking individuals aged 60 to 90 years with early-stage Alzheimer's disease and a progressive decline in cognitive function.
Not a fit: Patients with severe psychiatric conditions or those unable to undergo 7T MRI due to contraindications may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved predictive tools for monitoring Alzheimer's disease progression, potentially guiding treatment decisions.
How similar studies have performed: While the use of 7T MRI and MRS in Alzheimer's research is promising, this specific approach is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * French-speaking patients aged 60 to 90 years, * Patient in the context of Alzheimer's disease \* for which imaging after MRI is prescribed as part of the usual diagnostic process, \*Alzheimer's disease is diagnosed by the doctor of the memory consultation and is defined by :Evidence of a storage disorder in verbal episodic memory at LR/RI defined by a sum of LR \< 17/48 and sum of RT \< 40/48 +/- Impairment of executive functions possible (BREF, TMT grefex, verbal fluencies) +/- Impairment of instrumental functions possible (Grémots noun naming, Rey's figure, Mahieux's Battery). * MMSE score ≥18, * Written informed consent after the patient has been informed, * Progressive decline for at least 6 months. Exclusion Criteria: --Partially or completely illiterate patient unable to read and write, * Patient with an absolute contraindication to 7T MRI * Severe psychiatric pathology not balanced, * Non-degenerative neurological disease (stroke, multiple sclerosis ...), * Patient with tumor or inflammatory pathology, or vascular leukopathy visualized in MRI (Fazekas score \> 3)
Where this trial is running
Poitiers
- Chu Poitiers — Poitiers, France (Recruiting)
Study contacts
- Study coordinator: Adrien JULIAN, Dr
- Email: adrien.julian@chu-poitiers.fr
- Phone: 05.49.44.44.44
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.